Third-Quarter 2022 Results: Net Sales of $925.4 Million GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones
Rocket Pharmaceuticals (RCKT) Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
— Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort —
— Company to webcast. | September 16, 2022
Second-Quarter 2022 Results: Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Milli.